Theratechnologies Faces Supply Challenges
Theratechnologies Inc. has raised alarms about a possible temporary disruption in the supply of its main product, Egrifta SV (tesamorelin for injection). This situation could significantly affect the company’s revenue, primarily due to some unexpected delays in manufacturing.
Importance of Egrifta SV
Approved by the FDA, Egrifta SV is the only treatment available for HIV-related excess visceral abdominal fat. This product is crucial for patients facing specific health issues tied to HIV, which makes its steady availability vital.
Details of the Supply Disruption
The potential disruption arises from an unanticipated three-month voluntary shutdown of the contract manufacturer’s facility, following an FDA inspection. While these actions were necessary to tackle compliance observations, they didn’t directly impact the production of Egrifta SV but were related to the general environment of the facility.
Response from the Company
Paul Lévesque, the President and CEO of Theratechnologies, remains hopeful that the company can still meet the needs of patients despite these disruptions. To proactively address this issue, the company is implementing strategies to manage inventory levels of Egrifta SV until early January 2025, with the goal of ensuring a steady supply of the product.
Financial Consequences
In addition to operational hurdles, Theratechnologies expects these supply issues could lead to a revenue shortfall of around $1.6 million for its fiscal year 2024. This forecast underscores the importance of stable manufacturing processes and the financial risks associated with disruptions.
Manufacturer Shutdown and Future Plans
The contract manufacturer is expected to restart operations by mid-October, with initial production of Egrifta SV scheduled for October 21. To facilitate this process, Theratechnologies plans to submit a Prior Approval Supplement (PAS) to the FDA, which will outline the adjustments made at the facility. The FDA usually reviews such submissions within four months.
Dependence on Third-Party Suppliers
As previously mentioned, Theratechnologies does not have its own manufacturing facilities and depends on third-party suppliers such as Bachem, Jubilant, and Lyophilization Services of New England for the production of Egrifta SV. This reliance adds complexity, especially since the company hasn’t qualified alternative manufacturers. The validation process for new suppliers could take as long as three years, limiting production options.
Latest Stock Movements
Recently, THTX stock has climbed by 4.16%, reaching a value of $1.25. This uptick suggests a measure of investor confidence amidst the ongoing operational challenges.
Frequently Asked Questions
Why is Theratechnologies facing a supply disruption?
Theratechnologies is experiencing a supply disruption due to a voluntary shutdown of their contract manufacturer's facility following an FDA inspection.
What is Egrifta SV used for?
Egrifta SV serves as the only approved treatment for HIV-related excess visceral abdominal fat, which makes it essential for patients who require this therapy.
How long is the expected delay for Egrifta SV manufacturing?
Manufacturing is expected to resume by mid-October, with the first batch scheduled for production shortly thereafter.
What is the estimated revenue impact for Theratechnologies?
The company anticipates a revenue shortfall of around $1.6 million for the fiscal year 2024 due to these supply challenges.
How reliant is Theratechnologies on third-party manufacturers?
The company is heavily dependent on third-party suppliers since they do not have their own manufacturing facilities, complicating supply chain management.
